Skip to main content
Shandong Keyuan Pharmaceutical Co.,Ltd. logo

Shandong Keyuan Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 301281 ISIN · CNE1000061V8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 546 across all filing types
Latest filing 2026-05-25 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 301281

About Shandong Keyuan Pharmaceutical Co.,Ltd.

https://www.keyuanpharm.com

Shandong Keyuan Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of chemical raw materials and pharmaceutical preparations. The company focuses on several therapeutic areas, including diabetes, cardiovascular diseases, and mental health. Its core product portfolio features high-quality Active Pharmaceutical Ingredients (APIs) such as Metformin Hydrochloride, Gliclazide, and Isosorbide Mononitrate. Keyuan Pharmaceutical operates advanced production facilities compliant with international Good Manufacturing Practice (GMP) standards, enabling it to supply both domestic and global markets. The company integrates chemical synthesis with pharmaceutical formulation to provide comprehensive healthcare solutions, emphasizing technical innovation and quality control in its large-scale production processes.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东及其一致行动人权益变动触及1%整数倍暨减持股份计划完成公告
Major Shareholding Notification Classification · 93% confidence The document is an official shareholder announcement disclosing that an existing >5% shareholder and its concert parties have reduced their stake by 1% through centralized trading, triggering a change in major shareholding percentage. This is a classic “notification of changes in significant share ownership levels (crossing thresholds)” and corresponds to the Major Shareholding Notification category (MRQ).
2026-05-25 Chinese
关于持股5%以上股东部分股份解除质押的公告
Major Shareholding Notification Classification · 87% confidence The document is an official announcement by a shareholder holding more than 5% of the company’s shares regarding the partial release of pledged shares. It does not describe a company share buyback, management change, dividend, or full financial report. This type of disclosure is a Major Shareholding Notification regarding changes in the status of a significant shareholder’s holdings (share pledge/unpledge).
2026-05-20 Chinese
关于参加2026年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 85% confidence The document is a short public announcement about the company’s participation in an upcoming investor online reception event. It does not contain financial statements, voting results, management changes, or actual presentation materials. It is a general regulatory notice of an investor event, so it falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-13 Chinese
中信建投证券股份有限公司关于山东科源制药股份有限公司2025年度跟踪报告
Regulatory Filings Classification · 85% confidence The document is an annual “跟踪报告” (tracking report) prepared by the sponsor (中信建投证券) for the listed company 山东科源制药, covering sponsor’s review of company disclosures, governance supervision, on‐site inspections, special opinions, and the status of remedial measures over the 2025 reporting year. It is a regulatory compliance filing to the exchange, not an annual or interim financial report, earnings release, or management discussion, nor a simple announcement of a report. No specific category (e.g., 10-K, IR, ER, MDA) fits a sponsor’s tracking report, so it defaults to the general “Regulatory Filings” category.
2026-05-12 Chinese
2025年年度股东会决议公告
Regulatory Filings
2026-05-08 Chinese
北京德恒（济南）律师事务所关于山东科源制药股份有限公司2025年年度股东会的法律意见
Regulatory Filings
2026-05-08 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.